A randomized, placebo-controlled, double-blind, phase 3 trial to evaluate the efficacy and safety of anagliptin in drug-naïve patients with type 2 diabetes.
Yang HK, Min KW, Park SW, Chung CH, Park KS, Choi SH, Song KH, Kim DM, Lee MK, Sung YA, Baik SH, Kim IJ, Cha BS, Park JH, Ahn YB, Lee IK, Yoo SJ, Kim J, Park IeB, Park TS, Yoon KH.
Yang HK, et al.
Endocr J. 2015;62(5):449-62. doi: 10.1507/endocrj.EJ14-0544. Epub 2015 Mar 27.
Endocr J. 2015.
PMID: 25819061
Free article.
Clinical Trial.